Introduction
============

Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system (CNS) which presents with acute inflammatory episodes and co-occurring widespread neurodegeneration ([@B21]). These neuropathological processes are not only linked to physical disability progression, but also to cognitive impairment ([@B5]). The increasingly favorable mortality prognosis with new disease modifying therapies raises new questions about quality of life, the influence of frailty, prevalence of comorbidities, and cognitive aging among the elderly with MS (EwMS) ([@B26]; [@B14]).

Alzheimer's disease (AD) and its prodromal state, amnestic mild cognitive impairment (aMCI), are among the many comorbidities expected to increase within the aging population. Furthermore, the progressive MS phase is associated with neurodegenerative features resembling an AD-like phenotype. Although both diseases may lead to dementia, their cognitive hallmarks are thought to differ. MS patients commonly present with slowed cognitive processing speed (CPS) and deficient learning, a cognitive profile frequently associated with lesion disruption of neural networks and atrophy of major hubs that facilitate information exchange (e.g., thalamus) ([@B31]; [@B6]). Contrarily, AD is characterized by progressive decline in episodic memory, rapid forgetting, and impairments in semantic language. These defects are associated with neurodegeneration starting within the hippocampus, and entorhinal cortex ([@B11]; [@B17]; [@B22]). The prevalence of MS in the United States is now estimated at one million persons, and the average age of the population is increasing ([@B19]). Therefore, the possibility that an EwMS patient may develop AD should be considered with new onset cognitive complaints ([@B16]). Nevertheless, only a few case reports of MS and AD dual diagnosis are found in the literature ([@B16]). Therefore, understanding the cognitive profiles EwMS is highly warranted.

In a preliminary cross-sectional investigation, we compared EwMS (an average of 60 years old) with age and education-matched aMCI and AD patients ([@B24]). On a test of semantic verbal fluency, we found no significant difference between cognitively impaired MS and aMCI patients ([@B24]). Therefore, one may propose that as the MS cognitive decline progresses, additional cognitive features apart from processing speed are likely to emerge. Herein we endeavored to comprehensively examine the cognitive profile of a larger group of EwMS and age-matched healthy controls (HCs) using MS and AD-specific psychometric tests. We hypothesized that if EwMS have a true impairment in the language aspects of verbal fluency, this deficit should remain significant after controlling for the influence of cognitive processing speed.

Materials and Methods {#s1}
=====================

Study Population
----------------

The study sample was composed of prospectively enrolled EwMS and HCs. The inclusion criteria for EwMS were (1) age ≥50 years old, (2) neuropsychological and clinical examination, and (3) MS diagnosis per 2010-revised McDonald criteria ([@B20]). The exclusion criteria for the EwMS consisted of (1) history of psychiatric and major depressive disorder prior to the onset of MS, (2) active relapse within 30 days of the examination, and (3) use of corticosteroids within 30 days of the study. Inclusion and exclusion criteria for HCs were (1) ≥50 years old, (2) neuropsychological examination, (3) self-reported intact cognition, (4) no history of neurological or medical illness that might impact cognitive function, and (5) no diagnosis of major depressive disorder. Furthermore, HCs with mini-mental state examination (MMSE) performance lower than 28 were excluded. Both the EwMS and HCs were additionally screened with the beck depression inventory-II fastscreen (BDI-FS).

Clinical examination was performed by a neurologist and physical disability was assessed using the expanded disability status scale (EDSS) ([@B15]). The Timed 25-Foot Walk (T25FW) and 9-Hole Peg Test (9PHT) were additional measures of lower and upper extremity function, respectively. The EwMS were classified by disease course as relapsing-remitting MS (RRMS) and progressive MS (PMS). The study was approved by the Institutional Review Board (IRB) and all participants signed an informed consent form.

Neuropsychological Examination
------------------------------

The neuropsychological examination was performed by trained examiners under supervision of a board-certified neuropsychologist (RHBB) and included tests traditionally regarded as MS and AD-specific ([@B29]). The cognitive domains, their participating tests, and corresponding references are shown in [Table 1](#T1){ref-type="table"}.

###### 

Cognitive domains and their respective tests.

  Abbreviation                          Name                                                                References
  ------------------------------------- ------------------------------------------------------------------- ------------
  **Processing speed/working memory**                                                                       
  PASAT-3                               Paced Auditory Serial Addition Test (3 second version)              [@B10]
  SDMT                                  Symbol Digit Modalities Test                                        [@B27]
  **Learning and memory**                                                                                   
  CVLT-II total learning trials         California Verbal Learning Test (total score)                       [@B8]
  CVLT-II short delay                   California Verbal Learning Test (short delay score)                 [@B8]
  CVLT-II long delay                    California Verbal Learning Test (long delay score)                  [@B8]
  CVLT-II recognition index             California Verbal Learning Test (recognition index)                 [@B8]
  BVMT-R total learning trials          Brief Visuospatial Memory Test -- Revised (total immediate score)   [@B3]
  BVMT-R delay                          Brief Visuospatial Memory Test -- Revised (long delay score)        [@B3]
  BVMT-R recognition index              Brief Visuospatial Memory Test -- Revised (recognition index)       [@B3]
  WMS-R Logical Memory IR               Wechsler Memory Scale -- Revised (immediate recall score)           [@B32]
  WMS-R Logical Memory DR               Wechsler Memory Scale -- Revised (delayed recall score)             [@B32]
  WMS-R Logical Memory MR               Wechsler Memory Scale -- Revised (memory retention)                 [@B32]
  **Spatial processing**                                                                                    
  Beery VMI                             Beery-Buktenica Visual-Motor Integration Test                       [@B2]
  Clock drawing test                    N/A                                                                 [@B1]
  **Executive function**                                                                                    
  D-KEFS sorting CS                     Delis-Kaplan Executive Function System (correct sorts score)        [@B7]
  D-KEFS sorting DS                     Delis-Kaplan Executive Function System (description score)          [@B7]
  **Language**                                                                                              
  COWAT                                 Controlled Oral Word Association Test                               [@B25]
  BNT                                   Boston Naming Test                                                  [@B9]
  Animal fluency                        N/A                                                                 [@B25]
  Supermarket items fluency             N/A                                                                 [@B25]
  Total verbal fluency                  N/A                                                                 [@B25]
                                                                                                            

The exam included the Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS) battery ([@B4]) which evaluates several domains, including: processing speed/working memory \[Paced Auditory Serial Addition Test (PASAT) ([@B10]) and Symbol Digit Modalities Test (SDMT) ([@B27])\], learning and memory \[learning trials for California Verbal Learning Test--second edition (CVLT-II) ([@B8]) and Brief Visuospatial Memory Test-Revised (BVMT-R) ([@B3])\], language \[Controlled Oral Word Association Test (COWAT) ([@B25])\] and executive function \[number of correct sorts and description scores from the Sorting subtest of the Delis-Kaplan Executive Function System (D-KEFS) ([@B7])\].

Participants also completed neuropsychological measures that are traditionally utilized for detecting AD-specific cognitive impairments ([@B29]). These tests included those measuring the domains of memory \[Logical Memory from the Wechsler Memory Scale-Revised (WMS-R) ([@B32])\], language \[Boston Naming Test (BNT) ([@B9])\], two categories of semantic fluency (total number of categorical items generated in one minute; animals and supermarket items), and visuospatial skill \[Beery Visual-Motor Integration (VMI) ([@B2]) and clock drawing test ([@B1])\]. The MMSE was also performed as an additional assessment of descriptive global cognitive functioning. For all performed psychometric tests, higher scores indicate better cognitive performance.

Statistical Analysis
--------------------

All statistical tests were performed using SPSS version 25.0 (IBM, Armonk, NY, United States). The distribution of the variables was examined using both Kolmogorov-Smirnov and Shapiro-Wilk tests of normality. The differences in demographics and cognitive raw scores between EwMS and HCs were determined by χ^2^--test for categorical variables, ANOVA or *t*-test for continuous, normally distributed variables, and Mann Whitney *U*-test for continuous, not normally distributed variables. To control for the multiple comparisons, Benjamini-Hochberg procedure was employed and adjusted *p* \< 0.05 were considered statistically significant.

In order to delineate the degree of cognitive impairment across various cognitive domains while controlling for age, *z*-scores derived from the age-matched HCs were calculated. EwMS with *z*-score performance lower than -1.5 on at least two different cognitive domains were classified as cognitively impaired. The number of tests within each corresponding domain are shown in [Table 1](#T1){ref-type="table"}.

The impact of CPS on differences in cognitive performance between EwMS and HCs was additionally determined by analysis of covariance (ANCOVA) adjusted for SDMT scores.

Lastly, a multivariate logistic regression model determining the specific cognitive differences between the EwMS and the HCs was constructed. The model was composed of an initial force-entered block which corrected for differences in sex, age, and years of education. Furthermore, a second step-wise inclusion block determined the strength and order of cognitive variables which provided the greatest explanatory value in differentiating EwMS and HCs. For each derived step, the respective R^2^, Wald coefficient, and *p*-values were reported.

Results
=======

Demographic and Clinical Characteristics
----------------------------------------

The EwMS (*n* = 104) and HCs (*n* = 56) were similar in age (62.1 vs. 62.3 years, *p* = 0.919), years of education (15.2 vs. 15.6 years, *p* = 0.213) and sex ratio (75.0% vs. 62.5% females, *p* = 0.09). The MS group had a mean disease duration of 20.5 years, median EDSS scores of 3.5 (IQR 3.0--6.0), and ratio of RRMS/PMS of 73/31. Regarding disease modifying therapy (DMT), most EwMS were prescribed interferon-β (32, 30.8%), followed by glatiramer acetate (28, 17.3%), oral DMT medications (15, 14.4%), natalizumab (6, 5.8%), off-label medication (1, 0.9%), and the rest of the EwMS were not on any DMT (32, 30.8%).

The EwMS were more disabled when compared to the HCs in both lower and upper extremity function (T25FW, 6.7s vs. 4.7s, *p* \< 0.001; and 9PHT, 24.7s vs. 21.5s, *p* \< 0.001). The MS group also had higher depression scores (BDI-FS of 1.0 vs. 0.0, *p* = 0.005). All demographic and clinical information are shown in [Table 2](#T2){ref-type="table"}.

###### 

Demographic and clinical characteristics of the EwMS and HCs samples.

  Demographic and clinical characteristics   EwMS (*n* = 104)   HCs (*n* = 56)     Cohen's d   *p*-value
  ------------------------------------------ ------------------ ------------------ ----------- -------------
  Female, n (%)                              78 (75.0)          35 (62.5)          --          0.09
  Age, mean (SD)                             62.1 (6.3)         62.3 (8.1)         0.028       0.919
  Years of education, mean (SD)              15.2 (2.3)         15.6 (2.3)         0.174       0.213
  EDSS, median (IQR)                         3.5 (3.0-6.0)      \-                 --          --
  Disease duration, mean (SD)                20.5 (11.9)        \-                 --          --
  RRMS/PMS                                   73/31              \-                 --          --
  T25FW, median (IQR)                        6.7 (5.1-9.1)      4.7 (4.1-5.1)      **0.514**   **\<0.001**
  9-PHT, median (IQR)                        24.1 (22.1-29.5)   21.5 (20.4-23.5)   **0.532**   **\<0.001**
  BDI-II, median (IQR)                       1.0 (0.0-2.75)     0.0 (0.0-2.0)      **0.374**   **0.027**
  Disease modifying therapy, n (%)                                                             
  Interferon-β                               32 (30.8)          \-                 --          --
  Glatiramer acetate                         18 (17.3)          \-                 --          --
  Natalizumab                                6 (5.8)            \-                 --          --
  No DMT                                     32 (30.8)          \-                 --          --
  Oral DMT^∗^                                15 (14.4)          \-                 --          --
  Off-label medications                      1 (0.9)            \-                 --          --
                                                                                               

EwMS, elderly persons with multiple sclerosis; HCs, healthy controls; SD, standard deviation; IQR, interquartile ratio; RRMS, relapsing-remitting multiple sclerosis; PMS, progressive multiple sclerosis; BDI-II, Beck Depression Inventory; T25FW, Timed 25-Foot Walk; 9PHT, 9 Peg Hole Test; DMT, disease modifying therapy. Mann Whitney

U

-test, χ

2

, and Student's

t

-test were used accordingly.

P

-value lower than 0.05 was considered statistically significant.

∗

Oral DMTs include teriflunamide (9), dimethyl fumarate (5), and fingolimod (1). Use of off-label medications included only one case with rituximab. P-values lower than 0.05 were considered statistically significant and shown in bold.

Cognitive Performance, and *Z*-Score-Derived Domain-Specific Impairment Rates in the EwMS
-----------------------------------------------------------------------------------------

The raw scores from the neuropsychological examination of the EwMS and HCs on both the MACFIMS and AD-specific batteries are shown in [Table 3](#T3){ref-type="table"}. EwMS had lower raw scores when compared to the age-matched controls on both total learned and short delay recall in CVLT-II (49.7 vs. 54.9, *d* = 0.45, *p* = 0.018 and 9.8 vs. 11.2, *d* = 0.38, *p* = 0.045, respectively), SDMT (46.3 vs. 55.4, *d* = 0.91, *p* \< 0.001), letter verbal fluency (35.8 vs. 43.0, *d* = 0.67, *p* = 0.001) and category verbal fluency (17.3 vs. 20.3, *d* = 0.67, *p* = 0.001; 20.9 vs. 25.7, *d* = 0.84, *p* \< 0.001; and 38.2 vs. 45.9, *d* = 0.87, *p* \< 0.001, for animal category, supermarket category and total score, respectively). Furthermore, the EwMS had lower immediate recall and delayed recall scores on WMS-R logical memory performance (23.7 vs. 26.4, *d* = 0.39, *p* = 0.045 and 18.8 vs. 21.7, *d* = 0.38, *p* = 0.048). No other group differences were observed.

###### 

Cognitive performance of the EwMS and HCs populations on the minimal assessment for cognitive function in multiple sclerosis (MACFIMS) battery.

  Cognitive test                    EwMS (*n* = 104)   HCs (*n* = 56)   Cohen's d   *p*-value     BH-adjusted *p*-value^∗^
  --------------------------------- ------------------ ---------------- ----------- ------------- --------------------------
  CVLT-II total learning trials     49.7 (12.5)        54.9 (10.4)      **0.452**   **0.005**     **0.018**
  CVLT-II short delay               9.8 (4.1)          11.2 (3.3)       **0.376**   **0.02**      **0.045**
  CVLT-II long delay                10.7 (3.9)         11.9 (3.3)       0.581       0.029         0.053
  CVLT-II recognition index         2.9 (1.0)          3.3 (0.7)        0.463       0.111         0.167
  BVMT-R total learning trials      19.9 (7.1)         22.5 (5.6)       0.407       0.018         0.05
  BVMT-R delay                      8.1 (2.7)          8.5 (2.7)        0.148       0.309         0.412
  BVMT-R recognition index          5.5 (0.8)          5.5 (0.9)        0.0         0.634         0.667
  SDMT                              46.3 (10.8)        55.4 (9.2)       **0.907**   **\<0.001**   **\<0.001**
  PASAT-3                           41.5 (13.2)        45.8 (12.3)      0.337       0.05          0.077
  D-KEFS sorting CS^a^              9.0 (2.8)          9.3 (2.2)        0.119       0.579         0.644
  D-KEFS sorting DS^a^              33.6 (10.8)        34.9 (8.9)       0.131       0.448         0.559
  BNT                               56.1 (3.8)         56.9 (3.3)       0.225       0.179         0.256
  Letter-based verbal fluency       35.8 (11.2)        43.0 (10.2)      **0.672**   **\<0.001**   **\<0.001**
  Animal-based fluency              17.3 (4.7)         20.3 (4.3)       **0.666**   **\<0.001**   **0.001**
  Supermarket items-based fluency   20.9 (5.5)         25.7 (5.9)       **0.842**   **\<0.001**   **\<0.001**
  Total categorical fluency         38.2 (8.8)         45.9 (8.9)       **0.870**   **\<0.001**   **\<0.001**
  Beery VMI                         23.2 (3.3)         24.2 (2.6)       0.337       0.03          0.05
  Clock drawing test                8.9 (1.2)          9.1 (1.2)        0.167       0.505         0.594
  WMS-R logical memory IR           23.7 (7.1)         26.4 (6.4)       **0.399**   **0.018**     **0.045**
  WMS-R logical memory DR           18.8 (7.3)         21.7 (8.1)       **0.376**   **0.024**     **0.048**
  WMS-R logical memory MR           78.1% (14.8%)      79.3% (18.3%)    0.072       0.641         0.641
                                                                                                  

EwMS, elderly persons with multiple sclerosis; HC, healthy controls; MACFIMS, Minimal Assessment of Cognitive Function in Multiple Sclerosis; CVLT-II, California Verbal Learning Test; BVMT-R, Brief Visuospatial Memory Test -- Revised; SDMT, Symbol Digit Modalities Test; PASAT-3, 3 second Paced Auditory Serial Addition Test; D-KEFS, Delis-Kaplan Executive Function System; CS, number of correct sorts; DS, description score; BNT, Boston Naming Test; VMI, Visual-Motor Integration; WMS-R, Wechsler Memory Scale -- Revised; IR, immediate recall; DR, delayed recall; MR, memory retention. All variables are shown as the mean (SD) raw scores. For all tests, higher scores relate to better cognitive performance. Letter-based and categorical verbal fluency were examined by Controlled Oral Word Association Test (COWAT). Student's

t

-test was used

∗

Benjamini-Hochberg adjusted

p

-value \<0.05 was considered statistically significant and shown in bold.

a

77 out of 104 EwMS patients had available D-KEFS scores.

To investigate the influence of processing speed on our findings, we performed an analysis of covariance in which the COWAT differences (letter-based and category-based fluency) were adjusted by CPS performance (SDMT score as covariate). The performance on SDMT had a significant influence on letter-based verbal fluency performance (*F*~1,156~ = 39.5 *r* = 0.49, *p* \< 0.001). In the final model, EwMS and HCs were not significantly different in letter-based fluency scores when CPS was controlled (*F*~1,156~ = 3.9, *p* = 0.057). Processing speed also influenced the performance on total categorical verbal fluency (*F*~1,156~ = 34.2, *r* = 0.425, *p* \< 0.001) and on both animal-specific (*F*~1,156~ = 12.2, *r* = 0.242, *p* = 0.001), and supermarket items-specific category (*F*~1,156~ = 39.7, *r* = 0.476, *p* \< 0.001). Despite the large SDMT effect, categorical verbal fluency remained significantly different between the EwMS and HCs (adjusted *p* = 0.036, adjusted *p* \< 0.001, and adjusted *p* = 0.001, for animals, supermarket items, and total categorical verbal fluency, respectively).

Based on the HC-derived *z*-scores, the differences in processing speed and verbal fluency represented the most commonly affected domains in the EwMS. More than a quarter (27.9%) of EwMS had categorical verbal fluency impairment relative to HCs (22.1 and 24.0% for individual animal and supermarket tests, respectively). 25.0% were impaired on the letter-based verbal fluency, and 25.9% as impaired on the SDMT. Overall, 47.1% of the EwMS were classified as cognitively impaired on at least two different domain-specific tests. [Table 4](#T4){ref-type="table"} portrays the impairment rate observed for each cognitive test.

###### 

The ratio and percentage of cognitive impairment in the EwMS patients.

  Psychometric test               Impairment ratio   Psychometric test                 Impairment ratio
  ------------------------------- ------------------ --------------------------------- ------------------
  CVLT-II total learning trials   23/104 (22.1%)     D-KEFS Sorting DS                 14/77 (13.5%)
  CVLT-II short delay             23/104 (22.1%)     BNT                               10/104 (9.6%)
  CVLT-II long delay              18/104 (17.3%)     Animal-based fluency              23/104 (22.1%)
  CVLT-II recognition index       21/104 (20.2%)     Supermarket items-based fluency   25/104 (24.0%)
  BVMT-R total learning trials    23/104 (22.1%)     Total categorical fluency         29/104 (27.9%)
  BVMT-R delay                    11/104 (10.6%)     Beery VMI                         23/104 (22.1%)
  BVMT-R recognition index        12/104 (11.5%)     Clock drawing test                14/104 (13.5%)
  SDMT                            27/104 (25.9%)     WMS-R logical memory IR           19/104 (18.3%)
  PASAT-3                         18/104 (17.3%)     WMS-R logical memory DR           11/104 (10.6%)
  Letter-based verbal fluency     26/104 (25.0%)     WMS-R logical memory MR           6/104 (5.8%)
  D-KEFS Sorting CS               17/77 (16.3%)                                        
                                                                                       

CVLT-II, California Verbal Learning Test; SD, short delay; LD, long delay; BVMT-R, Brief Visuospatial Memory Test -- Revised; SDMT, Symbol Digit Modalities Test; PASAT-3, 3 second Paced Auditory Serial Addition Test; COWAT, Controlled Oral Word Association Test; D-KEFS, Delis-Kaplan Executive Function System; CS, number of correct sorts; DS, description score; BNT, Boston Naming Test; VMI, Visual-Motor Integration; WMS-R, Wechsler Memory Scale -- Revised; IR, immediate recall; DR, delayed recall; MR, memory retention. Cognitive impairment was defined as a score \<-1.5 SD relative to mean HC performance on the respective test. Letter-based and categorical verbal fluency were examined by Controlled Oral Word Association Test (COWAT).

Both the multivariate logistic regression model blocks and derived step-wise predictors are shown in [Table 5](#T5){ref-type="table"}. The diagnosis of MS was best predicted by differences in category-based verbal fluency (Wald = 9.935, *p* = 0.002) and SDMT (Wald = 13.937, *p* \< 0.001). Together with the force-entered block containing age, sex and years of education, the final step-wise model was able to explain 27% of the diagnosis variance (Nagelkerke *R*^2^ = 0.27). In terms of odds ratio (OR), for every point decrease in categorical verbal fluency, the chance of MS diagnosis increased for 8.1% \[Exp(B) = 0.919\]. Similarly, for every point decrease in SDMT, the change of MS diagnosis is increased for 9.3% \[Exp(B) = 0.907\].

###### 

Logistic regression model determining the cognitive differences between the EwMS and HCs.

                                    Nagelkerke R^2^   Wald coefficient   Exp(B)   *p*-value
  --------------------------------- ----------------- ------------------ -------- -------------
  **Block 1**                       0.04                                          
  Sex                                                 3.186              1.914    0.074
  Age                                                 0.022              0.996    0.883
  Years of education                                  1.973              0.901    0.16
  **Block 2**                                                                     
  Step 1:                           0.218                                         
  SDMT                                                22.992             0.885    **\<0.001**
  Step 2:                           0.27                                          
  SDMT                                                13.937             0.907    **\<0.001**
  Supermarket items-based fluency                     9.935              0.919    **0.002**
                                                                                  

EwMS, elderly with multiple sclerosis; HCs, healthy controls; SDMT, Symbol Digit Modalities Test. Block 1 force-entered the demographic characteristics (sex, age and years of education) regardless if they were significantly associated with the diagnosis. A second step-wise block included only significant differentiators between the EwMS and HCs. P-values lower than 0.05 were considered statistically significant and shown in bold.

Lastly, we investigated the associations between verbal fluency and cognitive processing speed with the overall disability scores as depicted by EDSS. Within the total sample of EwMS, EDSS scores were associated with both total verbal fluency (Spearman's ranked correlation, *r*~s~ = -0.292, *p* = 0.003) and SDMT performance (*r*~s~ = -0.398, *p* \< 0.001). Due to the nature of EDSS scoring system, we further delineated the EwMS into groups within the lower range of the score (EDSS scores between 0 and 4.0 which depend and reflect the neurological examination) and within the higher range of the score (EDSS scores ≥4.0 which solemnly depends on the walking ability) ([@B30]; [@B12]). As expected, the associations between cognitive performance and EDSS scores were mainly present within the subset of EwMS with lower EDSS scores (total verbal fluency *r*~s~ = -0.341, *p* = 0.001 and SDMT *r*~s~ = -0.398, *p* \< 0.001).

Discussion
==========

The main findings from this comprehensive neuropsychological evaluation of EwMS and age-matched HCs are grounded in two main themes. First, in addition to the previously established processing speed impairment, EwMS present with poorer verbal fluency (for both letter and category). Second, these findings were further extended by the logistic regression model which highlighted verbal fluency performance as second major differentiator between EwMS and HCs.

Currently there are few published analyses examining the question of comorbid aMCI/AD and cognitive aging in EwMS. [@B18] used an AD--specific battery to examine 120 total age-, sex-, and education-matched SPMS, aMCI, and HCs and found word list recognition as the single metric distinguishing SPMS from aMCI -- recognition memory was preserved in SPMS and defective in aMCI. Furthermore, they additionally showed that SPMS patients had similar performance on both letter-based and category-based verbal fluency when compared to the aMCI patients and significantly lower than HCs ([@B18]). In a similar study, EwMS were impaired on both processing speed and categorical fluency (Cohen's *d* = 0.68) when compared to HCs ([@B23]). Therefore, both studies are conforming to the present results showing a high rate of processing speed impairment and diminished verbal fluency performance in EwMS, but no differences in the recognition indices of both verbal memory and visuospatial processing ([@B24]). Although language impairment is classically associated with an AD cognitive profile, the deficits in processing speed and verbal fluency were not accompanied by deficits in naming and memory consolidation. Therefore, the verbal fluency deficits found here are likely attributable to MS rather than co-morbid aMCI/AD.

Verbal fluency tasks allow the participants only 1 min to produce as many words that start with a certain letter of the alphabet or are part of a specific category (e.g., animals or supermarket items). Given this predetermined time limitation, verbal fluency performance may potentially be moderated by processing speed, as we found in our adjusted model. Report by [@B23] showed that the EwMS have poorer categorical fluency when compared to HCs; however, after adjusting for CPS performance, these differences became non-significant. The discrepancy between our results and theirs is, however, minuscule (*d* 0.87 vs. 0.68 in [@B23]) -- the partial correlation survived in our study with *p* = 0.036 with more statistical power by virtue of a larger sample. Devising new language tests that are less dependent on CPS would be of value in this area of investigation. Finally, determining the nature of the language impairment and its association with specific structural MS changes will allow better understanding of this particular cognitive ability. For example, while examining neurodegenerative MS patterns, studies demonstrated accelerated atrophy of the entorhinal cortex and the bilateral temporal lobes in a population of older (on average of 57 years old) SPMS patients ([@B28]). These neurodegenerative changes located within AD-associated areas may provide explanation for the emerging semantic and logical memory deficit seen in our EwMS.

One limitation of this study is its cross-sectional research design. In order to better evaluate cognitive aging trajectories, ideally, one would evaluate these same cognitive functions over a period of three or more years, and include not only EwMS, but also aMCI patients. MRI-derived neurodegenerative outcome measures, amyloid PET imaging, assessment of known AD risk factors and the effect of other age-related comorbidities may further determine the nature of the semantic fluency impairment seen in EwMS ([@B13]). Lastly, global disability scores which are currently used in the MS field are not suitable in depicting the increasingly prevalent cognitive impairment within the aging MS population.

Conclusion
==========

In conclusion, roughly half of EwMS are impaired on tests of cognitive processing speed or verbal fluency. The deficit in verbal fluency is not a hallmark feature of MS associated cognitive disorder for the wider MS population, and may represent a unique quality in the EwMS neurocognitive profile. Further studies investigating the additional disease-related factors which influence cognitive aging in EwMS are warranted.
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